Evidence map›Paper›PMID 34577097›Full record

ReviewMolecules (Basel, Switzerland)2021

Repurposing Cardiac Glycosides: Drugs for Heart Failure Surmounting Viruses.

Jan Škubník, Jiří Bejček, Vladimíra Svobodová Pavlíčková, Silvie Rimpelová

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Pharmaceuticals (Basel, Switzerland) · 2024
    Article
  8. Article
  9. NaInternational journal of molecular sciences · 2024
    Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jan ŠkubníkDepartment of Biochemistry and Microbiology, University of Chemistry and Technology Prague, Technická 3, 16628 Prague, Czech Republic.ORCID 0000-0002-5633-2202
Jiří BejčekDepartment of Biochemistry and Microbiology, University of Chemistry and Technology Prague, Technická 3, 16628 Prague, Czech Republic.
Vladimíra Svobodová PavlíčkováDepartment of Biochemistry and Microbiology, University of Chemistry and Technology Prague, Technická 3, 16628 Prague, Czech Republic.ORCID 0000-0003-1055-4026
Silvie RimpelováDepartment of Biochemistry and Microbiology, University of Chemistry and Technology Prague, Technická 3, 16628 Prague, Czech Republic.ORCID 0000-0002-3008-1396

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug repositioning is a successful approach in medicinal research. It significantly simplifies the long-term process of clinical drug evaluation, since the drug being tested has already been approved for another condition. One example of drug repositioning involves cardiac glycosides (CGs), which have, for a long time, been used in heart medicine. Moreover, it has been known for decades that CGs also have great potential in cancer treatment and, thus, many clinical trials now evaluate their anticancer potential. Interestingly, heart failure and cancer are not the only conditions for which CGs could be effectively used. In recent years, the antiviral potential of CGs has been extensively studied, and with the ongoing SARS-CoV-2 pandemic, this interest in CGs has increased even more. Therefore, here, we present CGs as potent and promising antiviral compounds, which can interfere with almost any steps of the viral life cycle, except for the viral attachment to a host cell. In this review article, we summarize the reported data on this hot topic and discuss the mechanisms of antiviral action of CGs, with reference to the particular viral life cycle phase they interfere with.

Indexed as

Antiviral AgentsCardiac GlycosidesCOVID-19DigitoxinDigoxinDrug RepositioningHeart FailureHumansNeoplasmsOuabainPandemicsSARS-CoV-2Sodium-Potassium-Exchanging ATPaseVirus InternalizationVirus ReplicationAntiviral AgentsCardiac GlycosidesDigitoxinDigoxinOuabainSodium-Potassium-Exchanging ATPasecardiac steroidscoronavirusCOVID-19digitoxindigoxindrug repurposinglanatoside CNa+/K+-ATPaseouabainvirus entry

Identifiers

PMID34577097
PMCPMC8469069

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.